Skip to content
Part of the HERE CITY NETWORK Wednesday, November 18, 2026

National Deal News from the HERE CITY Network

Mergers & Acquisitions

J&J Agrees to Buy Ollin for $2.2 Billion; Blackstone Funds Trial

Johnson & Johnson will pay $2.2 billion upfront for eye-drug developer Ollin, with up to $1.125 billion more in milestones and Blackstone funding Phase 3.

Johnson & Johnson agreed to buy Ollin Biosciences Inc. for $2.2 billion in cash upfront, adding a late-stage eye-disease drug to its pipeline and bringing in Blackstone to pay for the final round of trials.

The New Brunswick, N.J., company said Monday that Ollin holders could receive up to about $1.125 billion more if the drug hits regulatory and sales milestones, taking the potential total to roughly $3.3 billion. The signed terms land just under the up-to-$3.4 billion figure that people familiar with the talks had described on Sunday. The deal is expected to close before the end of 2026, subject to regulatory approvals.

A minibody for the retina

Ollin, based in Austin, Texas, was founded in 2023 and is backed by ARCH Venture Partners and Mubadala Capital. Its lead program, OLN324, is a small-format bispecific antibody that blocks two drivers of retinal disease, vascular endothelial growth factor and angiopoietin-2. It is being developed for wet age-related macular degeneration and diabetic macular edema, which together affect more than 40 million people and are leading causes of vision loss. Ollin has begun enrolling patients in global Phase 3 trials for both conditions.

The drug was discovered by Hong Kong-listed Innovent Biologics, which licensed it to Ollin under the code IBI324. Innovent said in an exchange filing that it remains committed to advancing the program with its collaborators.

Blackstone pays for Phase 3

Alongside the purchase, J&J agreed to a development funding pact with Blackstone Life Sciences that takes effect at closing. Blackstone will pay J&J a total of $750 million over several years to fully fund Phase 3 development of OLN324. In exchange, it is eligible for certain regulatory and sales milestone payments plus single-digit royalties. J&J said it would disclose the accounting treatment on or before closing.

The arrangement lets J&J add a late-stage asset while shifting much of the trial cost to an outside investor. The company has a large contact lens business but a limited footprint in prescription eye drugs, and the deal is its biggest push yet into retinal disease. It joins a crowded run of biotech purchases by large drugmakers this fall, including AstraZeneca and its offer for Rhythm Pharmaceuticals and argenx buying Unnatural Products.

Sources

  1. jnj.com
  2. businesswire.com
  3. cnbc.com
  4. www1.hkexnews.hk

biotech blackstone life sciences johnson johnson mergers acquisitions ollin biosciences ophthalmology pharmaceuticals texas